Moderna Q2 EPS Increased by Brookline Capital Markets

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Brookline Capital Markets increased their Q2 2026 EPS estimates for shares of Moderna in a report released on Friday, July 31st. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of ($1.97) per share for the quarter, up from their previous estimate of ($1.98). The consensus estimate for Moderna’s current full-year earnings is ($6.41) per share. Brookline Capital Markets also issued estimates for Moderna’s Q3 2026 earnings at ($1.30) EPS, Q4 2026 earnings at ($2.16) EPS, FY2026 earnings at ($6.60) EPS and FY2027 earnings at ($3.24) EPS.

A number of other research analysts have also recently commented on MRNA. Wolfe Research reaffirmed an “underperform” rating and issued a $25.00 target price on shares of Moderna in a research report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Bank of America upped their price target on Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a research note on Tuesday, July 7th. Morgan Stanley increased their target price on Moderna from $33.00 to $39.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 8th. Finally, Royal Bank Of Canada boosted their price target on shares of Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating, nine have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $42.13.

Moderna Stock Performance

Shares of Moderna stock opened at $55.14 on Tuesday. Moderna has a 52 week low of $22.28 and a 52 week high of $85.60. The business’s fifty day simple moving average is $59.54 and its 200-day simple moving average is $52.75. The firm has a market cap of $21.88 billion, a PE ratio of -6.90 and a beta of 0.91. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.13) earnings per share.

Insider Transactions at Moderna

In related news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the sale, the insider owned 67,468 shares of the company’s stock, valued at approximately $3,373,400. This represents a 4.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 119,406 shares of company stock worth $5,928,762. 10.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. MUFG Securities EMEA plc purchased a new stake in shares of Moderna in the second quarter valued at about $28,000. Allied Private Wealth LLC acquired a new position in shares of Moderna during the 2nd quarter worth $30,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Moderna in the fourth quarter valued at about $31,000. Canton Hathaway LLC acquired a new position in Moderna during the first quarter worth about $31,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after acquiring an additional 801 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.